Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

Journal of Clinical Oncology

Volumn 23, Issue 11, 2005, Pages 2502-2512

  Spector, Neil L ^a   Xia, Wenle ^a   Burris III, Howard ^a   Hurwitz, Herbert ^a   Dees, E Claire ^a   Dowlati, Afshin ^a   O'Neil, Bert ^a   Overmoyer, Beth ^a   Marcom, Paul K ^a   Blackwell, Kimberly L ^a   Smith, Deborah A ^a   Koch, Kevin M ^a   Stead, Andrew ^a   Mangum, Steven ^a   Ellis, Matthew J ^a   Liu, Leihua ^a   Man, Albert K ^a   Bremer, Troy M ^a   Harris, Jennifer ^a   Bacus, Sarah ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR GROWTH; TUMOR REGRESSION; AGED; BIOASSAY; BIOSYNTHESIS; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 20244388653     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.157     Document Type: Article

References (41)

1. Slamon D, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
2. Bacus SS, Zelnich CR, Plowman G, et al: Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancer: Implication for tumor biology and clinical behavior. Am J Clin Pathol 102:S13-S24, 1994
3. Olayioye MA, Graus-Porta D, Beerli RR, et al: ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18:5042-5051, 1998
4. Fukazawa T, Miyake S, Band V, et al: Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem 271:14554-14559, 1996
5. Hackel PO, Zwick E, Prenzel N, et al: Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184-189, 1999
6. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287, 1996
7. Lange CA, Richer JK, Shen T, et al: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273:31308-31316, 1998
8. Bacus SS, Altomare DA, Lyass L, et al: AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21:3532-3540, 2002
9. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
10. Mendelsohn J, Baselga J: The EGF receptor as targets for cancer therapy. Oncogene 19:6550-6565, 2000
11. Xia W, Mullin RJ, Keith BR, et al: Antitumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263, 2002
12. Rusnak DW, Lackey K, Affleck K, et al: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94, 2001
13. Rusnak DW, Allfleck K, Cockerill SG, et al: The characterization of novel, dual ErbB2-2/EGFR tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 61:7196-7203, 2001
14. Cockerill S, Stubberfield C, Stables J, et al: Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett 11:1401-1405, 2001
15. Albanell J, Codony-Servat J: Rojo F, et al: Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous cell carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500-6510, 2001
16. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
18. Bacus S, Chin D, Stewart J, et al: Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers. Anal Quant Cytol Histol 19:316-328, 1997
19. Malik SN, Siu LL, Rowinsky EK, et al: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9:2478-2486, 2003
20. Koch KM, Lee D, Mangum S, et al: Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients. Eur J Cancer 1:559a, 2003 (suppl 5)
21. Spector N, Raefsky E, Hurwitz H, et al: Safety, clinical efficacy, and biologic assessments from EGF10004: A randomized Phase Ib study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or ErbB2. Proc Am Soc Clin Oncol 22:772a, 2003
22. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
23. Alimandi M, Romano A, Curia M, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821, 1995
24. Holbro T, Beerli RR, Maurer F, et al: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8938, 2003
25. DiGiovanna MP, Carter D, Flynn SD, et al: Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 74: 802-806, 1996
26. Thor AD, Liu S, Edgerton S, et al: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18:3230-3239, 2000
27. Vanhoefer U, Tewes M, Rojo F, et al: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22:175-184, 2004
28. Arteaga CL, Baselga J: Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practice. Clin Cancer Res 9:1579-1589, 2003
29. Rojo F, Tabernero J, Van Cutsem D, et al: Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839). Proc Am Soc Clin Oncol 22:191, 2003
30. Bishop PC, Myers T, Robey R, et al: Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21:119-127, 2002
31. Humphrey PA, Wong AJ, Vogelstein B, et al: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87:4207-4211, 1990
32. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
33. Lynch TJ, Bell D, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
34. Chang JC, Mohsin S, Weiss H, et al: Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab. Breast Cancer Res Treat 82:24a, 2003 (suppl 1)
35. Pommier Y, Sordet O, Antony S, et al: Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 23:2934-2949, 2004
36. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor 1 mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-207, 2002
37. Lu Y, Zi X, Zhao Y, et al: Insulin-like growth factor-1 receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857, 2001
38. Bacus S, Chin D, Maltzman W, et al: The efficacy of herceptin therapies is influenced by the expression of other ErbB receptors, their ligands and the activation of downstream signaling proteins. Br J Cancer 91:1190-1194, 2004
39. Balana ME, Labriola L, Salatino M, et al: Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20:34-47, 2001
40. Riese DJ, Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-48, 1998
41. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995